Sexually transmitted diseases treatment guidelines

Current Opinion in Pediatrics

Volumn 15, Issue 4, 2003, Pages 391-397

  Burstein, Gale R ^a,b   Workowski, Kimberly A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Adolescent medicine; Sexually transmitted diseases

Indexed keywords

ACICLOVIR; AZITHROMYCIN; BUTOCONAZOLE; CEFIXIME; CEFOTETAN; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; CLOTRIMAZOLE; DOXYCYCLINE; FAMCICLOVIR; FLUCONAZOLE; GYNAZOLE 1; IMIQUIMOD; ITRACONAZOLE; IVERMECTIN; KETOCONAZOLE; LEVOFLOXACIN; METRONIDAZOLE; MICONAZOLE; NONOXINOL; OFLOXACIN; PODOPHYLLOTOXIN; TERCONAZOLE; TIOCONAZOLE; VALACICLOVIR;

ADOLESCENT; CHLAMYDIASIS; CONDYLOMA; EVIDENCE BASED MEDICINE; FEMALE; GENITAL HERPES; GONORRHEA; HERPES SIMPLEX VIRUS; HUMAN; PELVIC INFLAMMATORY DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SCABIES; SEXUALLY TRANSMITTED DISEASE; SYPHILIS; TRICHOMONIASIS; VAGINA CANDIDIASIS; VAGINITIS; VIRUS INFECTION;

EID: 0043240293     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200308000-00006     Document Type: Review

References (32)

1. Centers for Disease Control and Prevention: Sexually Transmitted Diseases Surveillance, 2001. Atlanta, Georgia: U.S. Department of Health and Human Services, 2002:51-57.
2. Centers for Disease Control and Prevention: Sexually transmitted diseases treatment guidelines 2002. MMWR Morb Mortal Wkly Rep 2002, 51 (RR-6). Included in these guidelines are new alternative regimens for scabies, bacterial vaginosis, and early syphilis; an expanded section on the diagnosis of genital herpes (including type-specific serologic tests); a revised approach to the management of victims of sexual assault; and expanded regimens for the treatment of urethral meatal warts. In addition, these guidelines emphasize education and counseling for persons infected with HPV, clarify the diagnostic evaluation of congenital syphilis, and present information regarding the emergence of quinolone-resistant Neisseria gonorrhoeae and implications for treatment.
3. Centers for Disease Control and Prevention: 1998 Guidelines for the treatment of sexually transmitted diseases. MMWR Morb Mortal Wkly Rep 1998, 47(RR-1).
4. Stamm WE, Hicks CB, Martin DH, et al: Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men: a randomized double-blind study. JAMA 1995, 274:545-549.
5. Thorpe EM, Stamm WE, Hook EW, et al: Chlamydial cervicitis and urethritis: single dose treatment compared with doxycycline for seven days in community-based practices. Genitourin Med 1996, 72:93-97.
6. Hillis SD, Coles FB, Litchfield B, et al: Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women: a use-effectiveness study in public health settings. Sex Transm Dis 1998, 25:5-11.
7. Bachmann LH, Stephen J, Richey CM, et al: Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes: high therapeutic success rates despite poor compliance. Sex Transm Dis 1999, 26:272-278.
8. Schachter J: What is the minimally effective treatment for Chlamydia trachomatis infection? The compliance paradox Sex. Transm Dis 1998, 26:279-280.
9. Fortenberry JD, Brizendine E, Katz BP, et al: Subsequent sexually transmitted infections among adolescent women with genital infection due to Chlamydia trachomatis, Neisseria gonorrhoeae, or Trichomonas vaginalis. Sex Transm Dis 1999, 26:26-32.
10. Orr DP, Johnston K, Brizendine E, et al: Subsequent sexually transmitted infection in urban adolescents and young adults. Arch Pediatr Adolesc Med 2001, 155:947-953.
11. Burstein GR, Gaydos CA, Diener-West M, et al: Incident Chlamydia trachomatis infections among inner city adolescent females JAMA 1998, 280:521-526.
12. Whittington WL, Kent C, Kissinger P, et al: Determinants of persistent and recurrent Chlamydia trachomatis infection in young women: results of a multicenter cohort study. Sex Transm Dis 2001, 28:117-123.
13. Centers for Disease Control and Prevention: Increases in fluoroquinolone-resistant Neisseria gonorrhoeae: Hawaii and California, 2001. MMWR Morb Mortal Wkly Rep 2002, 51:1041-1044.
14. Burstein GR, Berman SM, Blumer JL, et al: Ciprofloxacin for the treatment of uncomplicated gonorrhea infection in adolescents: does benefit outweigh risk? Clin Infect Dis 2002, 35:S191-S199. This articles explains the rationale behind pediatric fluoroquinolone restrictions and presents an evidence-based pediatric safety profile.
15. Centers for Disease Control and Prevention: Notice to readers: discontinuation of cefixime tablets-United States. MMWR Morb Mortal Wkly Rep 2002, 51:1052.
16. Centers for Disease Control and Prevention: Oral alternatives to cefixime for the treatment of uncomplicated Neisseria gonorrhoeae urogenital infections. Availabe at: http://www.cdc.gov/std/treatment/Cefixime.htm. Accessed February 10, 2003. This article provides useful suggestions for treatment of uncomplicated N. gonorrhoeae genital infections if cefixime is unavailable.
17. Centers for Disease Control and Prevention: Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections-2002. MMWR Morb Mortal Wkly Rep 2002, 51 (RR15):1-27. This report emphasizes chlamydia screening. These guidelines consider tests from an economic perspective and expand the previous guidelines to address detection of N. gonorrhoeae as well as C. trachomatis infections. This report also addresses the need for additional testing after a positive screening test result to improve the specificity of a final diagnosis.
18. Koumans EH, Markowitz LE, Hogan V, et al: Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin Infect Dis 2002, 35:S152-S172. This article synthesizes available data on the treatment of nonpregnant and pregnant women with bacterial vaginosis to prevent preterm delivery. It provides the background information on which the STD Treatment Guidelines bacterial vaginosis management recommendations were made.
19. Madico G, Quinn TC, Rompalo A, et al: Diagnosis of Trichomonas vaginalis infection by PCR using vaginal swab samples. J Clin Microbiol 1998, 36:3205-3210.
20. Peipert JF, Ness RB, Soper DE, et al: Association of lower genital tract inflammation with objective evidence of endometritis. Infect Dis Obstet Gynecol 2000, 8:83-87.
21. Walker CK, Workowski KA, Washington AE, et al: Anaerobes in pelvic inflammatory disease: implications for the Centers for Disease Control and Prevention's guidelines for treatment of sexually transmitted diseases. Clin Infect 1999, 28:S29-36.
22. Wald A, Ashley-Morrow R: Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis 2002, 35:S173-S182. This article reviews the new serologic HSV-1 and HSV-2 tests and provides guidance on how and with whom they should be used.
23. Augenbraun M, Workowski K: Ceftriaxone therapy for syphilis: report from the emerging infections network. Clin Infect Dis 1999, 29:1337-1338.
24. Augenbraun MH: Treatment of syphilis 2001: nonpregnant adults. Clin Infect Dis 2002, 35(Suppl 2):S187-190.
25. Hook EW 3rd, Martin DH, Stephens J, et al: A randomized, comparative pilot study of azithromycin versus benzathine penicillin G for treatment of early syphilis. Sex Transm Dis 2002, 29:486-490.
26. Wiley DJ, Douglas J, Beutner K, et al: External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 2002 35:S210-S224. This article reviews external genital wart epidemiology and provides recommendations for their diagnosis, treatment, and prevention.
27. Wendel K, Rompalo A: Scabies and pediculosis pubis: an update of treatment regimens and general review. Clin Infect Dis 2002, 35:S146-S151. This article reviews scabies and pediculosis pubis presentation, treatment recommendations, and treatment rationale.
28. Richardson BA: Nonoxynol-9 as a vaginal microbicide for prevention of sexually transmitted infections. JAMA 2002, 287:1171-1172.
29. Centers for Disease Control and Prevention: Revised guidelines for HIV counseling, testing, and referral and revised recommendations for HIV screening of pregnant women. MMWR Morb Mortal Wkly Rep 2001, 50(RR19):1-86. These guidelines provide guidance to all public and private sector providers of voluntary HIV counseling, testing, and referral. Their recommendations include suggestions for targeted counseling, testing, and referral services through risk screening and other strategies.
30. Kamb ML, Fishbein M, Douglas JM, et al: HIV prevention counseling reduces high risk behaviors and sexually transmitted diseases: results from a multicenter, randomized controlled trial (Project RESPECT). JAMA 1998, 280:1161-1167.
31. Workowski KA, Levine WC, Wasserheit JN: U.S. Centers for Disease Control and Prevention Guidelines for the treatment of sexually transmitted diseases: an opportunity to unify clinical and public health practice. Ann Intern Med 2002, 137:255-262. This article provides a summary of the new recommendations in the 2002 CDC Guidelines for the Treatment of Sexually Transmitted Diseases in the context of current disease trends and public health.
32. Centers for Disease Control and Prevention: Youth risk surveillance-United States, 2001. MMWR Morb Mortal Wkly Rep 2002, 51 (SS-4):15-17.